Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study
pharmafile | June 4, 2020 | News story | Research and Development | Cosentyx, Novartis, axial spondyloarthritis
New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the therapy led to “significant and sustained improvements in signs and symptoms” of non-radiographic axial spondyloarthritis (nr-axSpA).
The debilitating condition is recorded as affecting around 1.7 million people across the largest five EU nations and the US, though, as a frequently undiagnosed condition, its true prevalence is likely much higher. Cosentyx secured approval in Europe for this indication in April this year.
The study revealed that biologic treatment-naïve participants receiving 150mg Cosentyx saw an improvement of 41.5% at 16 weeks and 35.4% at 52 weeks on the Assessment of Spondyloarthritis International Society (ASAS) assessment scale, compared to 29.2% and 19.9% over the same periods with placebo. With these results, the study met its primary endpoint of a 40% improvement, or ASAS40, in Cosentyx patients.
The trial also met its secondary endpoints over the 52 weeks, including improvements in pain, mobility and health-related quality of life.
“With these new data and the recent first-in-class European approval of Cosentyx in non-radiographic axial spondyloarthritis, we are continuing to build on our heritage in the axial spondyloarthritis disease spectrum,” said Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology at Novartis. “This fourth indication for Cosentyx further demonstrates our commitment to reimagine care for more patients.”
Matt Fellows
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …
Novartis to acquire MorphoSys AG for €2.7bn
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …